Biofidelity CMO Dr. Wendy Levin says the company has developed a novel genomic assay that can analyze DNA and RNA concurrently for NSCLC.
Credit
Biofidelity
Usage Restrictions
N/A
License
Original content
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.